e.l.f. Beauty (ELF) Q4 2026 earnings review
Top-Line Beats, But Unchecked SG&A Crushes Profitability
e.l.f. Beauty delivered a spectacular 35% YoY revenue surge in Q4, capping off a 25% growth year driven heavily by the outperformance of its Rhode acquisition. However, the top-line victory was entirely overshadowed by a massive collapse in profitability. Adjusted SG&A exploded to $300 million (66.8% of sales), driving a Reversing trend in Adjusted EBITDA, which fell 28% YoY. Furthermore, the massive success of Rhode triggered a $57.6 million earnout charge, pushing the company into a rare GAAP net loss of $49.4 million. Adding to concerns, management's FY27 guidance of 12-14% sales growth signals a stark deceleration, implying the core e.l.f. brand may be stagnating as Rhode carries the weight.
🐂 Bull Case
The $57.6 million fair value adjustment for Rhode's contingent consideration is a painful GAAP hit, but it proves the newly acquired brand is dramatically outperforming its revenue targets and driving massive top-line momentum.
Gross margin expanded 140 basis points YoY to 73% in Q4. The company successfully executed its $1 portfolio-wide price increase, entirely offsetting the severe China tariff headwinds that plagued the first half of the year.
🐻 Bear Case
Adjusted SG&A consumed an astonishing 66.8% of Q4 net sales (up from 52.1% a year ago). This aggressive marketing and distribution spend caused Adjusted EBITDA to plunge 28% despite 35% higher sales.
FY27 revenue guidance of 12-14% marks a sharp slowdown from FY26's 25% growth. With Rhode expected to grow rapidly, this implies the legacy e.l.f. portfolio is facing heavy stagnation or volume declines.
⚖️ Verdict: 🔴
Bearish. While gross margin recovery and Rhode's hyper-growth are impressive, the cost to acquire that growth has become exorbitant. A 13% Adjusted EBITDA margin in Q4 and guiding for severe top-line deceleration in FY27 strips away the structural bull narrative.
Key Themes
SG&A Spend Triggers Margin Collapse
A massive red flag emerged in operating expenses. Adjusted SG&A skyrocketed by $126.6 million to $300.0 million in Q4, representing 66.8% of net sales (up from 52.1% in 25Q4). Management cited marketing, merchandising, and compensation, but this level of spend completely fractured operating leverage. As a result, the Adjusted EBITDA margin Reversing violently, collapsing to 13.1% after averaging ~23% over the prior three quarters.
Rhode Outperformance Hits GAAP, Drives Strategy
The company recorded a massive $57.6 million expense for the change in fair value of contingent consideration related to the Rhode acquisition. While this pushed Q4 into a $49.4 million GAAP net loss, it is a highly bullish underlying signal: Rhode is generating revenue well above the earnout thresholds set during the merger. Rhode has definitively replaced the core e.l.f. brand as the primary growth engine.
Contradiction: Confidence vs. Decelerating Guidance
CEO Tarang Amin stated, 'The whitespace opportunity... gives us great confidence in the runway ahead.' However, this positive narrative directly contradicts their own FY27 guidance. Predicting 12-14% total growth implies a severe Decelerating trend compared to the 25% delivered in FY26. If Rhode is maintaining its guided >40% growth trajectory, the math suggests the core e.l.f. brand is bracing for flat or negative volume.
Macro Picture: Pricing Power Defeats Tariffs
A major bright spot is the company's handling of the China macro tariff situation. After facing punishing 55-170% tariff rates that dragged gross margins down in H1 FY26, the company's aggressive $1 portfolio-wide price hike has fully materialized. Q4 Gross Margin is Accelerating, expanding ~140 basis points YoY to 73.0%. Consumers accepted the higher prices without destroying top-line revenue.
International and Multi-Brand Expansion
The 35% Q4 revenue jump was explicitly credited to both retailer and e-commerce channel growth internationally and domestically. Naturium and Rhode were called out as delivering 'particularly strong results,' proving management's strategy to evolve from a single mass-market cosmetic label into a multi-brand powerhouse spanning skincare and prestige categories.
Debt Load and Rising Interest Burden
Fueling the Rhode acquisition came at a steep cost to the balance sheet. Total debt surged from $256.7 million at the end of FY25 to $841.7 million at the end of FY26. Consequently, net interest expense for the twelve months more than doubled to $35.3 million. While cash sits at a healthy $289.7 million, the company is highly leveraged to the continued outperformance of its acquired brands.
Other KPIs
Reversing sharply from $0.78 in the prior year quarter. Despite a massive 35% increase in net sales, the $126 million surge in Adjusted SG&A decimated bottom-line profitability on a per-share basis.
Accelerating from $133.8 million in FY25. Despite GAAP net income dropping heavily to $26.3 million due to the non-cash Rhode earnout charge ($57.6M) and elevated stock-based compensation ($86.9M), the underlying cash generation of the business remains robust.
Guidance
Decelerating. The midpoint of $1.85 billion implies 13% YoY growth. This is a dramatic slowdown from the 25% growth achieved in FY26 and the 35% growth printed in Q4, signaling tough upcoming comps and potential core portfolio stagnation.
Decelerating growth trajectory. The midpoint implies a 14% YoY increase, marginally outpacing revenue growth and suggesting an implied margin of roughly 20.6%. This indicates management expects to stabilize the margin run-rate compared to the dismal 13% seen in Q4, but offers no meaningful expansion beyond the FY26 average (20.5%).
Decelerating. The midpoint of $3.295 implies a meager 5.3% growth rate over FY26's $3.13. This heavily suppressed earnings growth profile highlights the drag of higher interest expenses and increased share counts stemming from M&A activity.
Key Questions
Structural SG&A vs Timing
Adjusted SG&A surged to nearly 67% of sales in Q4. How much of this $300 million quarterly spend represents a permanent, structural rebasing of your cost profile versus one-time campaign timing, and what is the exact targeted SG&A margin for FY27?
Core Portfolio Attrition
Your FY27 revenue guidance implies 12-14% growth. Considering the massive momentum and earnout beats of Rhode, does this outlook embed flat or negative volume growth for the legacy e.l.f. cosmetics brand?
Rhode Supply Chain Readiness
The $57.6 million earnout charge for Rhode indicates significant top-line outperformance against internal targets. Given this hyper-growth, what specific capacity or supply chain bottlenecks are you monitoring to ensure Rhode can fulfill continued global demand without stockouts?